# Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure

> **NCT01156636** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Milan** · enrollment: 44 (actual)

## Conditions studied

- Pulmonary Hypertension
- Diastolic Heart Failure

## Interventions

- **DRUG:** Sildenafil
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01156636
- **Lead sponsor:** University of Milan
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-09
- **Final completion:** 2009-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2012-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156636, "Phosphodiesterase-5 (PDE5) Inhibition and Pulmonary Hypertension in Diastolic Heart Failure". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01156636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*